BIOLOGIC AGENTS AND CAR T-CELL THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT EVIDENCE AND CLINICAL PERSPECTIVES - NARRATIVE REVIEW
Background Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which persistent activity, organ damage, glucocorticoid dependence, and treatment toxicity remain challenges. Advances in SLE immunopathogenesis have enabled pathway-targeted therapies, but their evidence and clinical readiness varie...